XML 20 R4.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Revenues $ 22,487,566 $ 17,938,790 $ 14,668,455
Cost of revenues 20,158,828 15,678,475 12,947,217
Research and development 23,899,026 29,194,262 16,917,396
Impairment of Intangible Assets, Finite-lived 62,273,336 0 0
Selling, general, and administrative 30,005,542 30,806,807 21,612,793
Operating Expenses 136,336,732 75,679,544 51,477,406
Operating loss (113,849,166) (57,740,754) (36,808,951)
Other income (expense):      
Other (expense) income, net 17,723,579 2,926,003 (1,614,858)
Interest expense (2,128,442) (755,697) (281,421)
Nonoperating Income (Expense), Total 15,595,137 2,170,306 (1,896,279)
Loss from operations before provision for income taxes and noncontrolling interests (98,254,029) (55,570,448) (38,705,230)
Income Tax Expense (Benefit) (17,243,528) (104,202) 780,104
Net loss (81,010,501) (55,466,246) (39,485,334)
Less - loss from continuing operations attributable to noncontrolling interests (124,549) (593,313) (504,090)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders $ (80,885,952) $ (54,872,933) $ (38,981,244)
Basic and diluted (loss) per share attributable to:      
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders $ (1.67) $ (1.68) $ (1.90)
Weighted average common shares outstanding 48,508,106 32,756,102 20,495,771